DRRX vs. CTMX, SELB, GLSI, IVA, LFCR, ABEO, CAPR, TRVI, OGI, and PBYI
Should you be buying DURECT stock or one of its competitors? The main competitors of DURECT include CytomX Therapeutics (CTMX), Selecta Biosciences (SELB), Greenwich LifeSciences (GLSI), Inventiva (IVA), Lifecore Biomedical (LFCR), Abeona Therapeutics (ABEO), Capricor Therapeutics (CAPR), Trevi Therapeutics (TRVI), Organigram (OGI), and Puma Biotechnology (PBYI). These companies are all part of the "medical" sector.
CytomX Therapeutics (NASDAQ:CTMX) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends.
CytomX Therapeutics received 56 more outperform votes than DURECT when rated by MarketBeat users. Likewise, 66.07% of users gave CytomX Therapeutics an outperform vote while only 65.15% of users gave DURECT an outperform vote.
67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 28.0% of DURECT shares are held by institutional investors. 7.0% of CytomX Therapeutics shares are held by company insiders. Comparatively, 4.3% of DURECT shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, CytomX Therapeutics had 1 more articles in the media than DURECT. MarketBeat recorded 2 mentions for CytomX Therapeutics and 1 mentions for DURECT. CytomX Therapeutics' average media sentiment score of 0.67 beat DURECT's score of 0.51 indicating that DURECT is being referred to more favorably in the news media.
CytomX Therapeutics has higher revenue and earnings than DURECT. DURECT is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.
CytomX Therapeutics presently has a consensus target price of $5.77, indicating a potential upside of 251.98%. DURECT has a consensus target price of $27.50, indicating a potential upside of 1,709.21%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe DURECT is more favorable than CytomX Therapeutics.
CytomX Therapeutics has a net margin of 13.87% compared to CytomX Therapeutics' net margin of -279.77%. DURECT's return on equity of -30.70% beat CytomX Therapeutics' return on equity.
CytomX Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, DURECT has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
Summary
CytomX Therapeutics beats DURECT on 13 of the 17 factors compared between the two stocks.
Get DURECT News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
